bpc 157 neuroprotection study Nerve Regeneration: Top 2026 Breakthrough BPC-157 Canada Research Guide 2026:

Efficacy of fixed-combination calcipotriene 0.005% and betamethasone dipropionate 0.064% foam for scalp plaque psoriasis: additional analysis of a phase II, randomized clinical study

The careful description is therefore: Barrier and InfiniWell sell consumer-facing BPC supplements, but their products are not FDA-approved BPC-157 drugs and should not be described as though approval or legal status has been affirmatively settled by their availability

pregnant or breastfeeding individuals (no safety data)

The double agonist means it has the potential to influence two receptors in test subjects during clinical trials

This mechanistic profile is why it appears in research spanning both areas

Published safety data comes entirely from animal studies, which show excellent tolerability with no reported serious adverse events